Endpoints News· @endpts · X·· 5 天前精选AI 评分58
AI 导读
百时美施贵宝将研发部门合并至首席医学官Cristian Massacesi之下,研究负责人Robert Plenge将离职。此次调整发生在Opdivo和Eliquis失去独家经营权之际。
推荐理由
百时美施贵宝将研发部门合并至首席医学官之下,读者可据此观察其研发组织调整与核心产品专利到期的关联。
正文
Bristol Myers is merging R&D under CMO Cristian Massacesi, with research head Robert Plenge set to exit as Opdivo and Eliquis lose exclusivity. https://endpoints.news/bristol-myers-to-merge-rd-under-massacesi-research-head-to-exit/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com